# OnCo record etn029 (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/etn029/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "etn029" ;
  schema:name "[225Ac]Ac-ETN029"@en ;
  schema:alternateName "ETN029"@en, "225Ac-ETN029"@en, "111In-ETN029"@en ;
  schema:description "[225Ac]Ac-ETN029 is an experimental radioligand therapy from Mariana Oncology, in phase 1 trials for small cell lung cancer, large cell neuroendocrine carcinoma of the lung and neuroendocrine prostate cancer and other cancers."@en ;
  schema:url <https://onco.cc/drugs/etn029/> ;
  schema:dateModified "2026-11-03"^^xsd:date ;
  schema:citation <https://marianaoncology.com/programs-and-pipeline/>, <https://marianaoncology.com/programs-and-pipeline/>, <https://clinicaltrials.gov/study/NCT07006727>, <https://clinicaltrials.gov/search?intr=ETN029> ;
  onco:status "phase-1" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:modality "Radioligand therapy (actinium-225)" ;
  onco:cancers <https://onco.cc/cancers/sclc/>, <https://onco.cc/cancers/lung-lcnec/>, <https://onco.cc/cancers/prostate/>, <https://onco.cc/cancers/extrapulmonary-nec/>, <https://onco.cc/cancers/neuroendocrine/> ;
  onco:targets <https://onco.cc/targets/dll3/> ;
  onco:companies <https://onco.cc/companies/mariana-oncology/>, <https://onco.cc/companies/novartis/> ;
  onco:trials <https://onco.cc/trials/nct07006727/> .